Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-11-19 THEUER CHARLES President and CEO Buy 4,181 $2.83 $11,831 No
2021-11-05 THEUER CHARLES President and CEO Buy 4,000 $3.41 $13,655 No
2021-01-27 THEUER CHARLES President and CEO Buy 11,000 $8.98 $98,771 No
2020-10-21 THEUER CHARLES President and CEO Buy 2,000 $4.38 $8,769 No
2020-09-23 THEUER CHARLES President and CEO Buy 5,000 $4.72 $23,599 No
2020-09-04 THEUER CHARLES President and CEO Buy 10,000 $2.58 $25,750 No
2020-08-21 THEUER CHARLES President and CEO Buy 5,325 $1.56 $8,307 No
2020-08-20 THEUER CHARLES President and CEO Buy 30,000 $1.58 $47,400 No
2020-08-18 THEUER CHARLES President and CEO Buy 44,843 $1.63 $73,021 No
2020-08-13 THEUER CHARLES President and CEO Buy 20,000 $1.73 $34,500 No
2020-06-24 THEUER CHARLES President and CEO Buy 9,895 $1.90 $18,800 No
2020-05-22 THEUER CHARLES President and CEO Buy 10,592 $1.90 $20,119 No
2020-03-13 THEUER CHARLES President and CEO Buy 4,100 $1.13 $4,624 No
2020-03-12 THEUER CHARLES President and CEO Buy 20,000 $1.43 $28,639 No
2020-03-10 THEUER CHARLES President and CEO Buy 10,000 $1.87 $18,691 No
2019-08-09 THEUER CHARLES President and CEO Buy 50,000 $0.45 $22,500 No
2018-12-21 THEUER CHARLES President and CEO Buy 49,000 $0.66 $32,222 No
2015-09-18 THEUER CHARLES President and CEO Sell 10,000 $17.34 $173,400 Yes
2015-09-10 THEUER CHARLES President and CEO Sell 3,516 $12.00 $42,192 No
2015-08-14 THEUER CHARLES President and CEO Sell 100 $12.00 $1,200 No

Insider Smart

Enphase Energy, Inc (ENPH) - ENPH was $10+ in 15Q1 then dropped to $2 and eventually went under $1. From 15Q4 to 17Q4 it built a 2-year-long base then BOOM! Stock went as high as $70 and likely will make a new high. Catch one or two moves like this you can retire early. One hint before the big move was that CEO and CFO were constantly accumulating, this kind of information is priceless.

Insider Smart

Delta Airlines (DAL) - From an insider's perspective: airlines are the first ones to go under due to the pandemic. A lot of concerns were raised on possible bankruptcy especially amid by the dump from Buffett. However, insiders of Delta were bold enough to buy when Buffett was fear. And Delta is the only airline bought by insiders post-Buffett-dump.